Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon-α (IFN-α) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)

Leukemia

Volumn 17, Issue 10, 2003, Pages 1919-1924

  Wassmann, B ^a   Scheuring, U ^a   Pfeifer, H ^a   Binckebanck, A ^a   Kabisch A ^b   Lubbert M ^c   Leimer, L ^d   Gschaidmeier, H ^e   Hoelzer, D ^a   Ottmann, O G ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Gie en and Novartis Pharma AG   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d ROBERT BOSCH HOSPITAL   (Germany)

^e Novartis Pharma AG   (Germany)

Author keywords

Acute lymphoblastic leukemia; BCR ABL; Imatinib; Interferon ; Minimal residual disease; Philadelphia chromosome

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; IMATINIB; MELPHALAN; RECOMBINANT ALPHA2A INTERFERON; THIOTEPA; ALPHA INTERFERON; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CANCER; BONE PAIN; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; LOW DRUG DOSE; MALE; MENINGEAL METASTASIS; MINIMAL RESIDUAL DISEASE; NEUTROPENIA; PAPILLEDEMA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; VISUAL DISORDER; CLINICAL TRIAL; MIDDLE AGED; MYELOID LEUKEMIA; PHASE 2 CLINICAL TRIAL; TIME; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 0142151254     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403093     Document Type: Article

References (40)

1. Gökbuget N, Hoelzer D, Arnold R. Treatment of adult ALL according to the protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am 2000; 14: 1307-1325.
2. Radich JP. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001; 15: 21-36.
3. Gökbuget N, Hoelzer D. Recent approaches in acute lymphoblastic leukemia in adults. Rev Clin Exp Hematol 2002; 6: 114-141.
4. Faderl S, Kantarjian HM, Thomas DA, Cortes J, Giles F, Pierce S et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leukemia Lymphoma 2000;36:263-273.
5. Gleißner B, Gökbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002; 99: 1536-1543.
6. Faderl S, Kantarjian HM, Thomas DA, Cortes J, Giles F, Pierce S et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leukemia Lymphoma 2000; 36: 263-273.
7. Hoelzer D, Gökbuget N. New approaches in acute lymphoblastic leukemia in adults: where do we go? Semin Oncol 2000; 27: 540-559.
8. Westbrook CA, Hooberman AL, Spino C, Dodge RK, Larson RA, Davey F et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood 1992; 80: 2983-2990.
9. Garcia-Manero G, Thomas DA. Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001; 15: 163-205.
10. Hoelzer D, Gökbuget N. Acute lymphoblastic leukemia in adults. In: Henderson ES, Lister TA, Greaves ME (eds). Leukemia. London: W.B. Saunders 2002, 621-655.
11. Thomas DA, Kantarjian H, Smith TL, Koller C, Cortes J, O'Brien S et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer 1999; 86: 1216-1230.
12. Dunlop LC, Powles R, Singhal S, Treleaven JG, Swansbury GJ, Meller S et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 1996; 17: 365-369.
13. Snyder DS, Nademanee AP, O'Donnell MR, Parker PM, Stein AS, Margolin K et al. Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia 1999; 13: 2053-2058.
14. Cornelissen JJ, Carston M, Kollman C, King R, Dekker AW, Lowenberg B et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001; 97: 1572-1577.
15. Martin TG, Gajewski JL. Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults. Hematol Oncol Clin North Am 2001; 15: 97-120.
16. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-145.
17. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
18. Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002; 1: 31-36.
19. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
20. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100: 1965-1971.
21. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164-172.
22. Sawyers CL. Signal transduction pathways involved in BCR-ABL transformation. Baillieres Clin Haematol 1997; 10: 223-231.
23. Wassmann B, Pfeifer H, Scheuring U, Binckebanck A, Atta J, Brück P et al. Treatment of Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) with the ABL-tyrosine kinase inhibitor imatinib mesylate (Glivec). Blood 2003 (in revision).
24. Hofmann WK, Jones LC, Lemp NA, de Vos S, Gschaidmeier H, Hoelzer D et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002; 99: 1860-1862.
25. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002; 359: 487-491.
26. Petzer AL, Gunsilius E, Hayes M, Stockhammer G, Duba HC, Schneller F et al. Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol 2002; 117: 623-625.
27. Takayama N, Sato N, O'Brien SG, Ikeda Y, Okamoto S. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukemia due to poor penetration into cerebrospinal fluid. Br J Haematol 2002; 119: 106-108.
28. Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001; 97: 1999-2007.
29. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 2000; 96: 3195-3199.
30. Visani G, Martinelli G, Piccaluga P, Tosi P, Amabile M, Pastano R et al. Alpha-interferon improves survival and remission duration in P-190BCR-ABL positive adult acute lymphoblastic leukemia. Leukemia 2000; 14: 22-27.
31. Visani G, Isidori A, Malagola M, Alberti D, Capdeville R, Martinelli G et al. Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed p190 BCR-ABL positive acute lymphoblastic leukemia. Leukemia 2002; 16: 2159-2160.
32. Scheuring UJ, Pfeifer H, Wassmann B, Brück P, Atta J, Petershofen E et al. Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl positive acute lymphoblastic leukemia (Ph+ALL with the ABL-tyrosine kinase inhibitor STI571 (Glivec). Blood 2003; 101: 85-90.
33. Wassmann B, Pfeifer H, Scheuring U, Klein SA, Gökbuget N, Binckebanck A et al. Therapy with imatinib mesylate (Glivec™) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia positive acute lymphoblastic leukemia (Ph+ALL). Leukemia 2002; 16: 2358-2365.
34. Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 2003; 304: 1085-1092.
35. Hofmann WK, Komor M, Wassmann B, Jones LC, Gschaidmeier H, Hoelzer D et al. Presence of the BCR-ABL mutation E255K prior to STI571 (imatinib) treatment in patients with Ph+ acutelymphoblastic leukemia. Blood 2003; 102: 659-661.
36. Burchert A, Wölfl S, Schmidt M, Brendel C, Denecke B, Cai D et al. Interferon a, but not the ABL-kinase inhibitor imatinib (STI571) induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 2003; 101: 259-264.
37. Nagafuji K, Harada N, Eto T, Hayashi S, Kamimura T, Gondo H et al. Interferon-alpha treatment of acute lymphoblastic leukemia relapse after unrelated bone marrow transplantation. Int J Hematol 1998; 67: 63-68.
38. Klingemann HG, Grigg AP, Wilkie-Boyd K, Barnett MJ, Eaves AC, Reece DE et al. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse. Blood 1998; 78: 3306-3311.
39. Mehta J, Powles R, Kulkarni S, Treleaven J, Singhal S. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients. Bone Marrow Transplant 1997; 20: 129-135.
40. Samson D, Volin L, Schanz U, Bosi A, Gahrton G. Feasibility and toxicity of interferon maintenance therapy after allogeneic BMT for multiple myeloma. A pilot study of the EBMT. Bone Marrow Transplant 1996; 17: 759-762.